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Abstract: A series of Mycobacterium tuberculosis TMPK (MtbTMPK) inhibitors based on a reported
compound 3 were synthesized and evaluated for their capacity to inhibit MtbTMPK catalytic activity
and the growth of a virulent M. tuberculosis strain (H37Rv). Modifications of the scaffold of 3 failed
to afford substantial improvements in MtbTMPK inhibitory activity and antimycobacterial activity.
Optimization of the substitution pattern of the D ring of 3 resulted in compound 21j with improved
MtbTMPK inhibitory potency (three-fold) and H37Rv growth inhibitory activity (two-fold). Moving
the 3-chloro substituent of 21j to the para-position afforded isomer 21h, which, despite a 10-fold
increase in IC50-value, displayed promising whole cell activity (minimum inhibitory concentration
(MIC) = 12.5 µM).
Keywords: tuberculosis; Mycobacterium tuberculosis; MtbTMPK; 1-(1-arylethylpiperidin-4-yl)thymine
1. Introduction
Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis
(M. tuberculosis). Still belonging to the top ten causes of death worldwide, TB was responsible
for claiming 1.5 million lives in 2018, thereby preceding AIDS [1]. The World Health Organization
(WHO) launched the “END TB” strategy in 2014, aiming at reducing the incidence of TB by 90%
and the number of deaths from TB by 95% by 2035 compared with 2015 levels [2]. Nevertheless, the
progress towards this sustainable development goal is disappointing, and the continuing increase in
drug-resistant TB cases makes the situation more challenging [1,3].
Patients with drug-sensitive TB are currently treated with a combination regimen, consisting of a
two-month treatment with first-line agents rifampicin, isoniazid, pyrazinamide and ethambutol, followed
by a four-month treatment with rifampicin and isoniazid. Although this schedule has decreased TB
mortality, these gains are being threatened by the advent of coinfection with HIV/AIDS, poor patient
adherence and a deficient health care system. Additionally, the emergence of multidrug-resistant
TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) further erodes the ambitions of the WHO
program [1]. In the case of MDR/XDR TB, a wide palette of second- and third-line anti-TB drugs are used,
e.g., fluoroquinolones, ethionamide, thioacetazone, clarithromycin and clofazimine [4,5]. However, this
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regimen not only requires more toxic and costly medications; it also requires a longer treatment duration
(up to 24 months), resulting in a poor outcome. Moreover, soon after their introduction, resistance has
already developed to the newly approved agents bedaquiline [6] and delamanid [7], with the use of
pretomanid restricted to a limited and specific population of patients [8]. Thus, novel anti-TB agents are
needed to effectively shorten the treatment regime and cure MDR-/XDR-TB.
Thymidylate kinase, a key enzyme for the synthesis of the DNA building block thymidine-5′-
triphosphate, is indispensable for bacterial survival [9–11]. The availability of co-crystal structures of
MtbTMPK [12–16] has aided the discovery of MtbTMPK inhibitors, featuring both nucleoside [14,17–20]
and non-nucleoside [14,15,20,21] structures.
A previous work from our laboratory started from compound 1 (Figure 1), originally reported
by AstraZeneca as an inhibitor of TMPK’s of Gram-positive bacteria [22]. After we found that it also
potently inhibited MtbTMPK, a SAR investigation demonstrated that it could be converted to the achiral
inhibitor 2 [14]. Further modifications led to the identification of 1-(1-arylethylpiperidin-4-yl)thymine
analog 3, which, compared to 1, displayed a nine-fold lower minimum inhibitory concentration (MIC)
value for H37Rv [14].
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In this manuscript, we describe our optimization efforts towards finding potent 
antimycobacterial agents based on 3 by introducing modifications on the A/B/C/D ring (Figure 2) and 
by altering the linker part. An overview of the synthesized analogs is presented in Figure 2. 
i 1. tructures of reported MtbTMPK inhib tors 1, 2 and 3 and their TMPK inhibitory potency and
tituberc la activity [14,20]. Compound 3 was resynthesized and re-evaluated herein as a reference.
MIC: minimum inhibitory concent ation.
In this manuscript, we describe our optimization efforts towards finding potent antimycobacterial
agents based on 3 by introducing modifications on the A/B/C/D ring (Figure 2) and by altering the
linker part. An overview of the synthesized analogs is presented in Figure 2.
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2. Results and Discussion
2.1. Chemistry
The envisioned analogs were synthesized according to a literature-reported procedure [14].
Briefly, the synthesis encompassed the reductive amination of N3-benzyloxymethyl (BOM)-protected
piperidinyl thymine with the appropriate aldehyde, followed by trifluoroacetic acid (TFA)-mediated
BOM deprotection to yield the desired analogs [14]. The required aldehyde intermediates (Scheme 1)
were obtained through the reduction of commercially available substituted methyl phenylacetate esters
with LiAlH4 [23] and subsequent re-oxidation by pyridinium chlorochromate (PCC) [24,25]. When
the required methyl esters were not commercial available, substituted phenoxy- or benzyloxyaryl
analogs were obtained through either Chan-Lam coupling of hydroxyphenylacetic methyl ester with a
boronic acid [26] or alkylation of the hydroxyphenylacetic methyl ester with benzyl bromide under
basic conditions [27].Molecules 2020, 25, 2805 4 of 22 
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tetrahydrofuran (THF); (b) pyridinium chlorochromate (PCC) and dichloromethane (DCM); (c) 
substituted phenylboronic acid, pyridine, 4Å molecular sieves, Cu(OAc)2 and 1,2-dichloroethane; (d) 
substituted benzyl bromide, K2CO3/Cs2CO3, NaI and dimethylformamide (DMF) and (e) substituted 
fluorobenzene, K2CO3, DMF and 90 °C. 
Due to the low yield of 17a–17c in the Chan-Lam coupling reaction, a different synthetic route 
was applied for the synthesis of aldehydes 18a–18c, which was based on nucleophilic aromatic 
substitution of the phenol with the appropriate 4-subsituted fluorobenzene [28]. Then, a PCC-
mediated oxidation furnished the desired aldehydes, which were used without further purification 
in the reductive amination step (Scheme 2). 
Scheme 1. Synthesis of crude aldehyde intermediates. Reagents and conditions: (a) LiAlH4
and tetrahydrofuran (THF); (b) pyridinium chlorochromate (PCC) and dichloromethane (DCM);
(c) substituted phenylboronic acid, pyridine, 4Å molecular sieves, Cu(OAc)2 and 1,2-dichloroethane;
(d) substituted benzyl bromide, K2CO3/Cs2CO3, NaI and dimethylformamide (DMF) and (e) substituted
fluorobenzene, 2C 3, F and 90 ◦C.
to the low yield of 17a–17c in the Chan-Lam coupling reaction, a different synthetic route was
applied for the synthesis of aldehydes 18a–18c, which was based on nucl ophilic aromatic substitution
of the phenol wi the appropr ate 4-subsituted fluorobenzene [28]. Then, a PCC-mediated oxidation
furnish the desired aldehydes, wh ch wer used ithout further purification in the reduc ve
amination step (Scheme 2).
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mediated BOM deprotection (Scheme 2) [29]. Potential dimerization during the TFA-mediated 
deprotection [14] was precluded by adding Et3SiH as a cation scavenger [29]. 
Amide 26 was obtained via N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC)-mediated 
coupling of 28 with 2-(3-phenoxyphenyl)acetic acid, which was obtained by hydrolysis of the 
corresponding methyl ester. The BOM group in the resulting amide intermediate was removed by 
catalytic hydrogenation with Pd/C [30]. 
A one-step reductive amination of 4-phenylpiperidine with aldehyde 12b afforded the phenyl 
analog 27. 
2.2. Biological Activity 
All synthesized compounds were evaluated for their capacity to inhibit MtbTMPK. Our 
previously reported analog 3, the starting point, was resynthesized and its reported inhibitory 
potency confirmed (Table 1, IC50 values of 11 and 17 μM, respectively) [14]. Replacement of the 
thymine ring by a phenyl (27) led to a complete loss of the inhibitory potency. Additionally, 
repositioning of the thymine ring from the para to the meta-position of the piperidine ring [20,22] 
Scheme 2. Synthesis of the final compounds. Reagents and conditions: (a) 28, sodium
triacetoxyborohydride and 1,2-dichloroethane; (b) trifluoroacetic acid (TFA), Et3SiH and 73 ◦C;
(c) (±)-29, sodium triacetoxyborohydride and 1,2-dichloroethane; (d) (i) aq. NaOH, MeOH and 50 ◦C;
(ii) 1N aq. HCl and H2O; (e) 28, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
(EDC.HCl), 4-dimethylaminopyridine (DMAP) and DCM; (f) Pd/C (10%), H2, HCOOH (0.5%)
and isopropanol/H2O (10/1 v/v) and (g) 4-phenylpiperidine, sodium triacetoxyborohydride and
1,2-dichloroethane.
Compounds 21a–21q and 23 were synthesized via reductive amination of N3-BOM-protected
piperidinyl thymine with the appropriate aldehyde [14], followed by trifluoroacetic acid (TFA)-mediated
BOM deprotection (Scheme 2) [29]. Potential dimerization during the TFA-mediated deprotection [14]
was precluded by adding Et3SiH as a cation scavenger [29].
Amide 26 was obtained via N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC)-mediated
coupling of 28 with 2-(3-phenoxyphenyl)acetic acid, which was obtained by hydrolysis of the
corresponding methyl ester. The BO group in the resulting amide intermediate was removed
by catalytic hydrogenation with Pd/C [30].
A one-step reductive amination of 4-phenylpiperidine with aldehyde 12b afforded the phenyl
analog 27.
2.2. Biological Activity
All synthesized compounds were evaluated for their capacity to inhibit MtbTMPK. Our previously
reported analog 3, he startin point, was resynthesized nd its reported inhibitory potency co firmed
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(Table 1, IC50 values of 11 and 17 µM, respectively) [14]. Replacement of the thymine ring by a phenyl
(27) led to a complete loss of the inhibitory potency. Additionally, repositioning of the thymine ring
from the para to the meta-position of the piperidine ring [20,22] (racemic compound 23) resulted in a
substantial (>10-fold) loss in the inhibitory potency. In-line with earlier observations, with a one-carbon
linker [14,21], amide analog 26 displayed a weak enzyme inhibition.
Table 1. Mycobacterium tuberculosis TMPK (MtbTMPK) inhibitory potency of the compounds.
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pose of compound 21  in MtbTMPK (Figur  3B) showed that the longated be zyloxy phenyl 
re ulted i  a weaker hydropho ic interaction with Tyr39 than the p noxy moiety of 3. Omitting the 
xyg n atom betwee  the two phenyl r ngs led to a complet loss f enzyme inhibitory otency 
(compound 21b). Moreover, moving the terminal phen xy ring f 3 to the ortho r para-positio  of 
ring C (c pounds 21c/21e) had a egativ  effect on the inh bitory activity. 
53 21n
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potency, our ef orts re then directed to ard the exploration of th  biphenyl ether tail. Deletion of 
the ter i al phenoxy g oup (analog 21a) resulted in a 40-fold decrease in inhibitory potency. Docking 
studies b sed  the X-ray co-cryst l str cture of tbT PK ith our previously reported 1-
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Docking indicated that the loss of a hydrophobic int raction ith Tyr39 accounts f r the rop in 
inhibitory potenc (Figure 3A). The ddition of a ethylene oiety bet ee  the ter inal p enyl ring 
a d C-phen xy group (analog 21n) caused a five-fold decr ase in t e inhibitory potency. T e ocki  
pose f co pound 21n in tbT PK (Figure 3B) sho ed that the elo gated be zyloxy phe yl 
re ulted i  a eaker hydropho ic interact on ith Tyr39 than t e p noxy oiety of 3. O it ing the 
oxygen ato  bet een the t  phenyl rings led to a co plete loss of enzy e inhibit r  ote cy 
(co pou d 21 ). oreov r, ovi g the ter inal phen xy ring f 3 t  the ortho r para-positio  of 
rin  C (compounds 21c/21 ) had a egative ef ect n the inhibitory ac ivity. 
95 ± 14
26
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a d C-phe xy group (a alog 21n) c use  a five-fold d crease in the inhibitory potency. T  ocki  
p se of compound 21n in MtbTMPK (Figure 3B) show d tha  th  elo gat d be zy oxy phe yl 
resul ed in a weaker hydrophobic interaction with Tyr39 th n e p oxy moi ty of 3. Omitting the 
oxygen at  b tween the tw  phenyl rin s l d to a ompl te loss of e z m  i hibit r  p t c  
(c mpou d 21 ). Moreov r, movi g the erminal phen xy ring of 3 t  the ortho or para-positio  of 
in  C (compounds 21c/21 ) ad a gativ  eff ct on the inhibi ory activi . 
230 ± 63 21c
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the ter in l phenoxy group (a alog 21 ) r sult d in a 40-fold decrease in in ibito y potency. ocki g 
studies based on the X-ray co-crystal s ructur  of tbT P  ith our pr viously eported 1-
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ock ng i dicated t at the loss f a hy rophob c interaction ith Tyr39 acc unts for the d op in 
inhib tory potency (Figure 3 ). The addition of a ethyl ne iety be een the ter inal p enyl ring 
and C-phe oxy group (analog 21n) c use  a five-fold d cr ase in the inhibitory po ency. The docking 
p se of co poun  21n in tb P  (Figure 3B) s o ed that e elongated be z loxy phenyl 
resulted in a aker hyd op obic interac i  ith Tyr39 th n th ph oxy oi ty of 3. it ing the 
oxygen ato  bet een the t o phe yl rings l d to a c pl e loss of e zy  inhibitory p tenc  
(c p und 21b). oreover, oving the ter inal phen xy ring of 3 to the or ho or para-posi on of 
ing C (co pounds 21c/21 ) ad a eg tive ef ec  on the in ibi ory activit . 
10 ± 15
21e
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earli r observatio s, with a one-carbon linker [14,21], amide a alog 26 d splayed a weak e zyme
inhibiti n. 
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a Values for which standard deviations are given are the calculated mean values of at least two 
me s rements. b NI: no inhibition at a concentratio  of 0.2 mM. 
Having established that 1-(1-arylethylpiperidin-4-yl)thymine is preferable for inhibitory 
potency, o r efforts were then ir cted toward th  exploration of th  b phenyl ether t il. Delet n of
the t rmin  ph oxy group (anal g 21 ) resulted i a 40-fold decreas  in inhibitory po ency. Docking
studi s based o  the X-ray co-cryst l str c ure of MtbTMPK with our pr viously eported 1-
( ip ridin-4-yl)thym n  in ibit r (PDB 5NR7) [14] were perf rmed to ratio aliz  th bserv d SAR.
D cking dica d t at the loss of a hyd ophobic interacti  wi Ty 39 accoun s f r th  dr p i
in ib tory potency (Fi ure 3A). The ddition of a methyl ne m iety b ween the terminal p nyl r
a d C-phe xy group (analog 21n) cause  a five-fold decrease in he in ibit ry potenc . The dock
pose of compoun 21n  Mtb MPK (Figure 3B) s ow d tha  e elong ted b z loxy phenyl
resulted in a w aker ydroph bic interac with Tyr39 than  p oxy moi ty of 3. Omitting the
oxyg n at m b tw en the tw  p nyl rin s led to a c mpl  loss of nzym  inhibitory p tenc
(c mp und 21 ). Moreov r, moving th  terminal phen xy ri g of 3 t  the o th or para-position of
ring C (compounds 21c/21 ) ad a gativ  effect on t e in ibitory ac ivi .
160 ± 22
a Values for which standard deviations are given are the calculated mean values of at least two measurements. b NI:
no inhibition at a concentration of 0.2 mM.
Having established that 1-(1-arylethylpiperidin-4-yl)thymine is preferable for inhibitory potency,
our efforts were then directed toward the exploration of the biphenyl ether tail. Deletion of the terminal
phenoxy group (analog 21a) resulted in a 40-fold decrease in inhibi ory potency. Docking studies based
on the X-ray co-crystal structure f MtbTMPK with our previously reported 1-(piperidin-4-yl)thymine
inhibitor (PDB 5NR7) [14] were performed to rationalize the observed SAR. Docking indicated that the
loss of a hydrophobic interaction with Tyr39 accounts for the drop in inhibitory potency (Figure 3A).
The addition of a methylene moiety between the terminal phenyl ring and C-phenoxy group (analog
21n) caused a five-fold decrease in the inhibitory potency. The docking pose of compound 21n in
MtbTMPK (Figure 3B) showed that the elongated benzyloxy phenyl resulted in a weaker hydrophobic
interaction with Tyr39 than the phenoxy moiety of 3. Omitting the oxygen atom between the two
phenyl rings led to a complete loss of enzyme inhibitory potency (compound 21b). Moreover, moving
the terminal phenoxy ring of 3 to the ortho or para-position of ring C (compounds 21c/21e) had a
negative effect on the inhibitory activity.
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Figure 3. (A) Structure overlay of compound 3 (cyan) and 21a (yellow) docked in the MtbTMPK (PDB 
5NR7) [14] active site. (B) Structure overlay of compound 3 (cyan) and 21n (green) docked in the 
MtbTMPK (PDB 5NR7) [14] active site. All residues interacting with the inhibitors, including the 
hydrophobic contact (gray wire) and hydrogen-bonding interaction (residues in orange wire, 
hydrogen bonds indicated in magenta), were calculated using LigPlus [31]. Illustration was created 
using Chimera [32]. 
Based on these results, further optimization efforts focused on the substitution pattern of the 
terminal phenyl ring of 3 and 21n. As shown in Table 2, most of the substituted analogs exhibited a 
small decrease in inhibitory activity compared to 3. Of note, the introduction of sterically demanding 
electron withdrawing substituents (21k/21l/21m) resulted in a significant drop in MtbTMPK 
inhibitory potency. 
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49 ± 8 21o 
 
70 ± 9 
Figure 3. (A) Structure overlay of compound 3 (cyan) and 21a (yellow) docked in the MtbTMPK
(PDB 5NR7) [14] active site. (B) Structure overlay of compound 3 (cyan) and 21n (green) docked in
the MtbTMPK (PDB 5NR7) [14] active site. All residues interacting with the inhibitors, including
the hydrophobic contact (gray wire) and hydrogen-bonding interaction (residues in orange wire,
hydrogen bonds indicated in magenta), were calculated using LigPlus [31]. Illustration was created
using Chimera [32].
Based on these results, further optimization efforts focused on the substitution pattern of the
terminal phenyl ring of 3 and 21n. As shown in Table 2, most of the substituted analogs exhibited a small
decrease in inhibitory activity compared to 3. Of note, the introduction of sterically demanding electron
withdrawing substituents (21k/21l/21m) resulted in a significant drop in MtbTMPK inhibitory potency.
Table 2. MtbTMPK inhibitory activity of the compounds.
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Interestingly, the introduction of a 3-chloro (21j) but not a 4-chloro substituent (21h) afforded
a significant improvement in the inhibitory potency due to an edge-to-face π-stacking interaction
between the 3-chlorobenzene ring and Tyr39, as found for compound 3 (Figure 4). Introduction of a
3-chloro substituent in the benzyl analog 21n also had a beneficial impact on the inhibitory activity.
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21j, with the side chain of Tyr39. All residues interacting with the inhibitors, including the 
hydrophobic contact (gray wire) and hydrogen-bonding interaction (residues in orange wire, 
hydrogen bonds indicated in magenta), were calculated using LigPlus [31]. Illustration was created 
using Chimera [32]. 
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Figure 4. (A) Structure overlay of compound 3 (cyan), 21j (yellow) and 21h (purple) in the MtbTMPK
(PDB 5NR7) [14] active site. (B) Detailed representation of the interactions of the D rings of 3, 21h and
21j, with the side chain of Tyr39. All residues interacting with the inhibitors, including the hydrophobic
contact (gray wire) and hydrogen-bonding interaction (residues in orange wire, hydrogen bonds
indicated in magenta), were calculated using LigPlus [31]. Illustration was created using Chimera [32].
Finally, all compounds were evaluated for their in vitro antimycobacterial activity (Table 3).
Consistent with the observations on the enzyme inhibitory activities, modifications of the scaffold of 3
did not yield analogs with superior antimycobacterial activity (21a-21c, 21e, 21n, 23 and 26). Remarkably,
analog 27, in which the thymine moiety is replaced by a phenyl ring, showed potent antimycobacterial
activity but lacked selectivity, as evidenced by its equipotent cytotoxicity. The introduction of
substituents on the distal phenyl ring of 3 afforded several analogs with improved antimycobacterial
activity (21f–21j). Substitution of the D-ring of the benzyloxy analog 21n also contributed to the growth
inhibitory activity. However, the selectivity vs. MRC-5 fibroblasts was modest.
Table 3. Antimycobacterial activity against H37Rv and cytotoxicity against MRC-5 fibroblasts of the





( RC-5, µM) SI
b Compound MIC(H37Rv, µM)
IC50
(MRC-5, µM) SI
3 37 >64 >1.73 21k ≥50 >64 -
21a >50 >64 - 21l 37 >64 >1.73
21b >50 22.22 - 21m 37 >64 >1.73
21c 50 26.81 0.54 21n 37 27.57 0.74
21e >50 >64 - 21o 19 7.08 0.37
21f 19 8.42 0.44 21p 12.5 4.22 0.34
21g 19 5.66 0.30 21q 25 19.84 0.79
21h 12.5 5.81 0.46 23 >50 21.77 -
21i 25 >64 >2.56 26 >50 >64 -
21j 19 25.24 1.33 27 6.25 8.06 1.29
a Minimum inhibitory concentration (MIC) is the minimum concentration required to inhibit >99% growth of
Mycobacterium tuberculosis H37Rv in the liquid culture. b Selectivity index (SI): IC50 (MRC-5)/MIC (H37Rv).
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3. Materials and Methods
3.1. Enzymatic Assay
The enzymatic assay was performed as previously reported on the recombinant purified
MtbTMPK [14,33]. As described by Blondin et al. [34], compounds were evaluated by a serial
dilution method using the spectrophotometric assay at fixed concentrations of adenosine triphosphate
(ATP) (0.5 mM) and thymidine monophosphate (dTMP; 0.05 mM). The reaction medium includes
50-mM Tris-HCl; pH 7.4; 50-mM KCl; 2-mM MgCl2; 0.2-mM nicotinamide adenine dinucleotide
(NADH); 1-mM phosphoenol pyruvate and 2 units each of coupling enzymes (lactate dehydrogenase,
pyruvate kinase and nucleoside diphosphate kinase). From the experimental data, the IC50 value was
calculated using KaleidaGraph 4.5.3.
3.2. Computational Studies
For the molecular modeling, X-ray structure of the MtbTMPK (PDB entry 5NR7 [14]) was analyzed
using AutoDock vina and AutodockTools-1.5.6. [35]. In ChemDraw 3D 16.0, the PDB files of all ligands
were generated after the energy was minimized (minimum RMS gradient: 0.001). The PDBQT file
of the ligands and receptors were prepared by AutodockTools-1.5.6, including atom types, atomic
partial charges and the information on the ligand torsional degrees. Using a grid spacing of 0.375 and
60 × 60 × 60 numbers of grid points, the prepared PDBQT files of ligands and receptors were docked
(centered on the MtbTMPK active site PHE70 CE2, the coordinates x, y and z were −0.997, 26.240 and
−4.528, correspondingly) through the Lamarckian 4.2 method. Each ligand was docked in Autodock
vina 3 times, with each time generating 20 possible conformations. Chimera in combination with
LigPlus were used to analyze the results.
3.3. In Vitro Antituberculosis Assay
The MIC values of all compounds were determined as previously described [36]. In brief,
M. tuberculosis H37Rv (ATCC 27294) was grown to optical density at 650 nm wavelength (OD650nm)
0.2 in Middlebrook 7H9 medium supplemented with 0.4% glucose, 0.03% Bacto casitone and 0.05%
Tyloxapol (7H9/glucose/casitone/Tyloxapol) prior to further 1000-fold dilution in fresh medium.
Drugs were 2-fold serially diluted in duplicate in 7H9/glucose/casitone/Tyloxapol (50 µL/well) in a
concentration range spanning 100-0.049 µM in sterile 96-well U-bottom clear polystyrene microtiter
plates. Isoniazid and DMSO as positive and negative controls, respectively. An equal volume (50 µL)
of diluted cells was added to the plates with the serial drug dilution. Plates were sealed in Ziplock
bags and incubated at 37 ◦C. After 7–14 days, plates were read with an enlarging inverted mirror plate
reader. The MIC was recorded as the concentration that fully inhibited all visible growth.
3.4. In Vitro Cytotoxicity Assay
The cytotoxicity of compounds on MRC-5 fibroblasts was performed exactly as previously
reported [14].
3.5. Chemistry
All reagents and solvents were purchased from standard commercial sources and were of
analytical grade. All synthetic compounds described in this study were checked with analytical TLC
(Macherey−Nagel precoated F254 aluminum plates, Düren, Germany), visualized under UV light
at 254 nm and purified by column chromatography (CC) on a Reveleris X2 (Grace, BÜCHI, Flawil,
Switzerland) automated flash unit. All final compounds and some intermediates were measured
with Varian Mercury 300/75 MHz (Palo Alto, CA, USA) or a Bruker AVANCE (Fällanden, Zürich,
Switzerland) Neo® 400/100 MHz spectrometer at 298.15 K using tetramethylsilane (TMS) as an internal
standard. The analysis and confirmation of the final compounds were conducted with 1H, 13C,
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HSQC and HMBC NMR spectral data (Supplementary Materials). High-resolution mass spectrometry
was performed on a Waters LCT Premier XETM (Waters, Zellik, Belgium) time-of-flight (TOF) mass
spectrometer equipped with a standard electrospray ionization (ESI) and modular LockSprayTM
interface (Waters, Zellik, Belgium). The purity of the tested compounds was determined by LC-MS
analysis using a Waters AutoPurification system equipped with a Waters Cortecs C18 column (2.7 µm,
100 × 4.6 mm), as was a gradient system of formic acid in H2O (0.2%, v/v)/MeCN with a gradient of
95:5 to 0:100 in 6.5 min at a flow rate of 1.44 mL/min.
General procedure A: Synthesis of biphenyl ether aldehyde building blocks. According to a
literature report [26], hydroxyphenylacetic ester derivatives (1.0 eq), phenylboronic acid derivatives
(3.0 eq.), Cu(OAc)2 (2.0 eq.), 4Å molecular sieves (0.18 g/mmol ester) and pyridine (3.0 eq.) in
1,2-dichloroethane (6.0 mL/mmol ester) afforded the biphenyletheracetic ester intermediates. To a
solution of the biphenyletheracetic ester intermediates (1.0 eq.) in dry tetrahydrofuran (THF)
(6.0 mL/mmol ester intermediate) was added LiAlH4 (2.0 eq.) at 0 ◦C under N2 atmosphere, and the
resulting mixture was then stirred at room temperature for 1 h [23]. After complete consumption of the
starting material, the reaction mixture was quenched with aq. Na+/K+ tartrate solution (5.0 mL/mmol
LiAlH4), and the mixture was stirred at room temperature overnight and then filtered. The collected
filtrate was dried and concentrated to afford a crude alcohol intermediate, which was oxidized by PCC
(2.0 eq.) for 2 h in dichloromethane (DCM) (5.0 mL/mmol PCC) [24,25]. The reaction mixture was
filtered through a short silica column. The collected filtrate was concentrated in vacuo and used in the
next step without any additional purification.
General procedure B: Synthesis of final compounds. To a solution of aldehyde intermediates
(1.0 eq.) and 28 (1.0 eq.) in 1,2-dichloroethane (33 mL/mmol aldehyde) was added sodium
triacetoxyborohydride (2.0 eq.). The resulting mixture was stirred at room temperature for overnight to
afford the BOM-protected intermediate [14], which was deprotected with TFA (17 mL/mmol aldehyde)
in the presence of triethylsilane [29] (17 mL/mmol aldehyde) at 73 ◦C for 4 h. After cooling down to
room temperature, the reaction mixture was evaporated in vacuo to remove TFA, and the residue was
adjusted to pH 6 with 1N aq. HCl. Purification of the resulting mixture by column chromatography
gave the desired compounds.
2-([1,1’-Biphenyl]-4-yl)acetaldehyde (6). To a solution of methyl 2-([1,1’-biphenyl]-4-yl)acetate (0.3 g,
1.3 mmol) in dry THF (7.8 mL) was added LiAlH4 (0.10 g, 2.7 mmol) to give alcohol intermediate,
which was oxidized with PCC (0.56 g, 2.6 mmol) in DCM (13.0 mL) to yield aldehyde 6 (C14H12O,
0.22 g, 1.1 mmol).
2-(2-Phenoxyphenyl)acetaldehyde (12a). Following the general procedure A, methyl
2-(2-hydroxyphenyl)acetate (1.1 g, 8.1 mmol), phenylboronic acid (2.9 g, 24 mmol), Cu(OAc)2
(2.9 g, 16 mmol), 4Å molecular sieves (1.5 g) and pyridine (1.9 mL, 24 mmol) in 1,2-dichloroethane
(49 mL) afforded the ester intermediate methyl 2-(2-phenoxyphenyl)acetate 10a (eluent system: 10%
ethylacetate in petroleum ether, C15H14O3, 0.40 g, 1.6 mmol, 21% yield). 1H NMR (300 MHz, CDCl3)
δ ppm 3.63 (s, 3 H, OCH3), 3.72 (s, 2 H, CH2), 6.90 (dd, J = 8.1, 1.0 Hz, 1 H, Ph), 6.95–7.01 (m, 2 H,
Ph), 7.06–7.15 (m, 2 H, Ph), 7.21–7.37 (m, 4 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 35.6 (1 C, CH2),
51.8 (1 C, OCH3), 118.3 (2 C, Ph), 118.8 (1 C, Ph), 123.0 (1 C, Ph), 123.6 (1 C, Ph), 125.8 (1 C, Ph), 128.6
(1 C, Ph), 129.6 (2 C, Ph), 131.4 (1 C, Ph), 155.0 (1 C, Ph), 157.2 (1 C, Ph), 171.7 (1 C, CO). Then, 10a
(0.20 g, 0.83 mmol) was treated with LiAlH4 (63 mg, 1.7 mmol) in dry THF (5.0 mL) to give alcohol
intermediate, which was oxidized with PCC (0.34 g, 1.6 mmol) in DCM (8.0 mL) to yield aldehyde 12a
(C14H12O2, 0.15 g, 0.70 mmol).
2-(3-Phenoxyphenyl)acetaldehyde (12b). Following the general procedure A, methyl
2-(3-hydroxyphenyl)acetate (1.1 g, 8.1 mmol), phenylboronic acid (2.9 g, 24 mmol), Cu(OAc)2
(2.9 g, 16 mmol), 4Å molecular sieves (1.5 g) and pyridine (1.9 mL, 24 mmol) in 1,2-dichloroethane
(49 mL) afforded the ester intermediate methyl 2-(3-phenoxyphenyl)acetate 10b (eluent system: 10%
ethylacetate in petroleum ether, C15H14O3, 0.80 g, 3.3 mmol, 41% yield). 1H NMR (300 MHz, CDCl3)
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δppm 3.62 (s, 2 H, CH2), 3.71 (s, 3 H, OCH3), 6.90 - 6.95 (m, 1 H, Ph), 6.98 (t, J = 2.1 Hz, 1 H, Ph),
7.01–7.07 (m, 3 H, Ph), 7.13 (tt, J = 7.4, 1.1 Hz, 1 H, Ph), 7.26–7.40 (m, 3 H, Ph). 13C NMR (75 MHz,
CDCl3) δppm 40.9 (1 C, CH2), 52.0 (1 C, OCH3), 117.3 (1 C, Ph), 119.0 (2 C, Ph), 119.7 (1 C, Ph), 123.3
(1 C, Ph), 124.0 (1 C, Ph), 129.7 (3 C, Ph), 135.7 (1 C, Ph), 156.9 (1 C, Ph), 157.4 (1 C, Ph), 171.6 (1 C,
CO). Then, 10b (0.20 g, 0.83 mmol) was treated with LiAlH4 (63 mg, 1.7 mmol) in dry THF (5.0 mL)
to give alcohol intermediate, which was oxidized with PCC (0.35 g, 1.6 mmol) in DCM (8.0 mL) to
yield aldehyde 12b (C14H12O2, 0.15 g, 0.71 mmol).
2-(4-Phenoxyphenyl)acetaldehyde (12c). Following the general procedure A, methyl
2-(4-hydroxyphenyl)acetate (0.60 g, 4.4 mmol), phenylboronic acid (1.6 g, 13 mmol), Cu(OAc)2
(1.6 g, 8.8 mmol), 4Å molecular sieves (0.70 g) and pyridine (1.1 mL, 13 mmol) in 1,2-dichloroethane
(26 mL) afforded the ester intermediate methyl 2-(4-phenoxyphenyl)acetate 10c (eluent system: 10%
ethylacetate in petroleum ether, C15H14O3, 0.66 g, 2.7 mmol, 62% yield). 1H NMR (300 MHz, CDCl3) δ
ppm 3.63 (s, 2 H, CH2), 3.72 (s, 3 H, OCH3), 6.95–7.06 (m, 4 H, Ph), 7.08–7.15 (m, 1 H, Ph), 7.23–7.29 (m,
2 H, Ph), 7.31–7.39 (m, 2 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 40.3 (1 C, CH2), 52.0 (1 C, OCH3),
118.8 (4 C, Ph), 123.2 (1 C, Ph), 128.7 (1 C, Ph), 129.6 (2 C, Ph), 130.5 (2 C, Ph), 156.3 (1 C, Ph), 157.0 (1 C,
Ph), 172.0 (1 C, CO). Then, 10c (0.20 g, 0.83 mmol) was treated with LiAlH4 (63 mg, 1.6 mmol) in dry
THF (5.0 mL) to give alcohol intermediate, which was oxidized with PCC (0.3 g, 1.4 mmol) in DCM
(7.0 mL) to yield aldehyde 12c (C14H12O2, 0.13 g, 0.62 mmol).
2-(3-(p-Tolyloxy)phenyl)acetaldehyde (12d). Following the general procedure A, methyl
2-(3-hydroxyphenyl)acetate (0.60g, 4.4 mmol), p-tolylboronic acid (1.8 g, 13 mmol), Cu(OAc)2 (1.6 g,
8.8 mmol), 4Å molecular sieves (0.79 g) and pyridine (1.1 mL, 13 mmol) in 1,2-dichloroethane
(26 mL) afforded the ester intermediate methyl 2-(3-(p-tolyloxy)phenyl)acetate 10d (eluent system: 10%
ethylacetate in petroleum ether, C16H16O3, 0.34 g, 1.3 mmol, 30% yield). 1H NMR (300 MHz, CDCl3) δ
ppm 2.37 (s, 3 H, CH3), 3.62 (s, 2 H, CH2), 3.72 (s, 3 H, OCH3), 6.89–6.99 (m, 4 H, Ph), 7.00–7.05 (m, 1 H,
Ph), 7.14–7.21 (m, 2 H, Ph), 7.25–7.32 (m, 1 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 20.6 (1 C, CH3),
40.9 (1 C, CH2), 51.9 (1 C, OCH3), 116.7 (1 C, Ph), 119.1 (3 C, Ph), 123.5 (1 C, Ph), 129.6 (1 C, Ph), 130.1
(2 C, Ph), 132.9 (1 C, Ph), 135.6 (1 C, Ph), 154.4 (1 C, Ph), 157.9 (1 C, Ph), 171.6 (1 C, CO). Then, 10d
(0.20 g, 0.78 mmol) was treated with LiAlH4 (59 mg, 1.6 mmol) in dry THF (4.7 mL) to give alcohol
intermediate, which was oxidized with PCC (0.28 g, 1.3 mmol) in DCM (6.5 mL) to yield aldehyde 12d
(C15H14O2, 0.13 g, 0.58 mmol).
2-(3-(3,4-Dichlorophenoxy)phenyl)acetaldehyde (12e). Following the general procedure A, methyl
2-(3-hydroxyphenyl)acetate (0.60 g, 4.4 mmol), (3,4-dichlorophenyl)boronic acid (2.5 g,
13 mmol), Cu(OAc)2 (1.6 g, 8.8 mmol), 4Å molecular sieves (0.79 g) and pyridine
(1.1 mL, 13 mmol) in 1,2-dichloroethane (26 mL) afforded the ester intermediate methyl
2-(3-(3,4-dichlorophenoxy)phenyl)acetate 10e (eluent system: 10% ethylacetate in petroleum ether,
C15H12Cl2O3, 0.73 g, 2.3 mmol, 53% yield). 1H NMR (300 MHz, CDCl3) δ ppm 3.63 (s, 2 H, CH2), 3.71
(s, 3 H, OCH3), 6.86 (dd, J = 8.9, 2.8 Hz, 1 H, Ph), 6.90–6.99 (m, 2 H, Ph), 7.06–7.12 (m, 2 H, Ph), 7.31 (d,
J = 7.9 Hz, 1 H, Ph), 7.37 (d, J = 8.8 Hz, 1 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 40.8 (1 C, CH2),
52.1 (1 C, OCH3), 117.8 (1 C, Ph), 118.0 (1 C, Ph), 120.2 (1 C, Ph), 120.3 (1 C, Ph), 125.1 (2 C, Ph), 130.0
(1 C, Ph), 130.9 (1 C, Ph), 133.1 (1 C, Ph), 136.1 (1 C, Ph), 156.1 (1 C, Ph), 156.3 (1 C, Ph), 171.5 (1 C,
CO). Then, 10e (0.20 g, 0.64 mmol) was treated with LiAlH4 (49 mg, 1.3 mmol) in dry THF (3.8 mL) to
give alcohol intermediate, which was oxidized with PCC (0.23 g, 1.1 mmol) in DCM (5.5 mL) to yield
aldehyde 12e (C14H10Cl2O2, 0.10 g, 0.36 mmol).
2-(3-(4-Chlorophenoxy)phenyl)acetaldehyde (12f). Following the general procedure A, methyl
2-(3-hydroxyphenyl)acetate (0.60 g, 4.4 mmol), (4-chlorophenyl)boronic acid (2.1 g, 13 mmol), Cu(OAc)2
(1.6 g, 8.8 mmol), 4Å molecular sieves (0.79 g) and pyridine (1.1 mL, 13 mmol) in 1,2-dichloroethane
(26 mL) afforded the ester intermediate methyl 2-(3-(4-chlorophenoxy)phenyl)acetate 10f (eluent
system: 10% ethylacetate in petroleum ether, C15H13ClO3, 0.40 g, 1.4 mmol, 33% yield). 1H NMR
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(300 MHz, CDCl3) δ ppm 3.62 (s, 2 H, CH2), 3.71 (s, 3 H, OCH3), 6.87–6.99 (m, 4 H, Ph), 7.05 (d,
J = 7.3 Hz, 1 H, Ph), 7.25–7.34 (m, 3 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 40.9 (1 C, CH2), 52.1 (1
C, OCH3), 117.4 (1 C, Ph), 119.8 (1 C, Ph), 120.2 (2 C, Ph), 124.5 (1 C, Ph), 128.4 (1 C, Ph), 129.8 (2 C, Ph),
129.9 (1 C, Ph), 136.0 (1 C, Ph), 155.7 (1 C, Ph), 157.1 (1 C, Ph), 171.6 (1 C, CO). Then, 10f (0.20 g, 0.72
mmol) was treated with LiAlH4 (55 mg, 1.5 mmol) in dry THF (4.3 mL) to give alcohol intermediate,
which was oxidized with PCC (0.31 g, 1.5 mmol) in DCM (7.5 mL) to yield aldehyde 12f (C14H11ClO2,
0.13 g, 0.53 mmol).
2-(3-(4-Methoxyphenoxy)phenyl)acetaldehyde (12g). Following the general procedure A, methyl
2-(3-hydroxyphenyl)acetate (0.60 g, 4.4 mmol), (4-methoxyphenyl)boronic acid (2.0 g,
13 mmol), Cu(OAc)2 (1.6 g, 8.8 mmol), 4Å molecular sieves (0.79 g) and pyridine
(1.1 mL, 13 mmol) in 1,2-dichloroethane (26 mL) afforded the ester intermediate methyl
2-(3-(4-methoxyphenoxy)phenyl)acetate 10g (eluent system: 10% ethylacetate in petroleum ether,
C16H16O4, 0.33 g, 1.2 mmol, 28% yield). 1H NMR (300 MHz, CDCl3) δ ppm 3.60 (s, 2 H, CH2), 3.70 (s, 3
H, OCH3), 3.82 (s, 3 H, (Ph)OCH3), 6.82–6.87 (m, 1 H, Ph), 6.88–6.94 (m, 3 H, Ph), 6.95–7.03 (m, 3 H,
Ph), 7.22–7.29 (m, 1 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 41.0 (1 C, CH2), 52.0 (1 C, OCH3), 55.6 (1
C, (Ph)OCH3), 114.8 (2 C, Ph), 116.0 (1 C, Ph), 118.4 (1 C, Ph), 120.9 (2 C, Ph), 123.2 (1 C, Ph), 129.6
(1 C, Ph), 135.6 (1 C, Ph), 149.8 (1 C, Ph), 155.9 (1 C, Ph), 158.6 (1 C, Ph), 171.7 (1 C, CO). Then, 10g
(0.20 g, 0.74 mmol) was treated with LiAlH4 (56 mg, 1.5 mmol) in dry THF (4.4 mL) to give alcohol
intermediate, which was oxidized with PCC (0.32 g, 1.5 mmol) in DCM (7.5 mL) to yield aldehyde 12g
(C15H14O3, 0.14 g, 0.58 mmol).
2-(3-(3-Chlorophenoxy)phenyl)acetaldehyde (12h). Following the general procedure A, methyl
2-(3-hydroxyphenyl)acetate (0.40 g, 2.9 mmol), 3-chlorophenylboronic acid (1.4 g, 8.8 mmol), Cu(OAc)2
(1.1 g, 5.9 mmol), 4Å molecular sieves (0.50 g) and pyridine (0.71 mL, 8.8 mmol) in 1,2-dichloroethane
(17 mL) afforded the ester intermediate methyl 2-(3-(3-chlorophenoxy)phenyl)acetate 10h (eluent
system: 10% ethylacetate in petroleum ether, C15H13ClO3, 0.28 g, 1.0 mmol, 34% yield). 1H NMR
(300 MHz, CDCl3) δ ppm 3.63 (s, 2 H, CH2), 3.71 (s, 3 H, OCH3), 6.88–6.96 (m, 2 H, Ph), 6.98 (t, J = 1.9 Hz,
1 H, Ph), 7.00 (t, J = 2.2 Hz, 1 H, Ph), 7.04–7.14 (m, 2 H, Ph), 7.17–7.36 (m, 2 H, Ph). 13C NMR (75 MHz,
CDCl3) δ ppm 40.9 (1 C, CH2), 52.1 (1 C, OCH3), 116.8 (1 C, Ph), 117.9 (1 C, Ph), 118.9 (1 C, Ph), 120.2
(1 C, Ph), 123.3 (1 C, Ph), 124.8 (1 C, Ph), 130.0 (1 C, Ph), 130.5 (1 C, Ph), 135.0 (1 C, Ph), 136.0 (1 C, Ph),
156.5 (1 C, Ph), 158.1 (1 C, Ph), 171.5 (1 C, CO). Then, 10h (0.20 g, 0.72 mmol) was treated with LiAlH4
(55 mg, 1.4 mmol) in dry THF (4.3 mL) to give alcohol intermediate, which was oxidized with PCC
(0.19 g, 0.87 mmol) in DCM (4.3 mL) to yield aldehyde 12h (C14H11ClO2, 0.10 g, 0.41 mmol).
2-(3-(Benzyloxy)phenyl)acetaldehyde (15a). According to a literature procedure [27] with minor changes,
methyl 2-(3-hydroxyphenyl)acetate (0.30 g, 2.2 mmol), benzyl bromide (0.26 mL, 2.2 mmol), K2CO3
(0.61 g, 4.4 mmol), sodium iodide (33 mg, 0.22 mmol) in dimethylformamide (DMF) (10 mL) at room
temperature for overnight afforded the ester intermediate methyl 2-(3-(benzyloxy)phenyl)acetate 13a
(eluent system: 10% ethylacetate in petroleum ether, C16H16O3, 0.33 g, 1.3 mmol, 58% yield). 1H NMR
(300 MHz, CDCl3) δ ppm 3.65 (s, 2 H, CH2), 3.73 (s, 3 H, OCH3), 5.10 (s, 2 H, (Ph)CH2O), 6.83–7.05 (m,
3 H, Ph), 7.21–7.52 (m, 6 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 41.1 (1 C, CH2), 52.0 (1 C, OCH3),
69.8 (1 C, (Ph)CH2O), 113.4 (1 C, Ph), 115.8 (1 C, Ph), 121.8 (1 C, Ph), 127.5 (2 C, Ph), 127.9 (1 C, Ph),
128.5 (2 C, Ph), 129.5 (1 C, Ph), 135.4 (1 C, Ph), 136.9 (1 C, Ph), 158.9 (1 C, Ph), 171.8 (1 C, CO). Then, 13a
(0.20 g, 0.78 mmol) was treated with LiAlH4 (59 mg, 1.6 mmol) in dry THF (4.7 mL) to give alcohol
intermediate, which was oxidized with PCC (0.34 g, 1.6 mmol) in DCM (8.0 mL) to yield aldehyde 15a
(C15H14O2, 0.14 g, 0.62 mmol).
2-(3-((2-Chlorobenzyl)oxy)phenyl)acetaldehyde (15b). Following the procedure as described for 15a, methyl
2-(3-hydroxyphenyl)acetate (0.40 g, 2.9 mmol), 1-(bromomethyl)-2-chlorobenzene (0.60 g, 2.9 mmol),
K2CO3 (0.81 g, 5.9 mmol), sodium iodide (44 mg, 0.29 mmol) in DMF (13 mL) afforded the ester
intermediate methyl 2-(3-((2-chlorobenzyl)oxy)phenyl)acetate 13b (eluent system: 10% ethylacetate in
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petroleum ether, C16H15ClO3, 0.26 g, 0.89 mmol, 30% yield). 1H NMR (300 MHz, CDCl3) δ ppm 3.63
(s, 2 H, CH2), 3.71 (s, 3 H, OCH3), 5.17 (s, 2 H, (Ph)CH2O), 6.86–7.01 (m, 3 H, Ph), 7.23–7.36 (m, 3 H,
Ph), 7.41 (dd, J = 7.0, 2.1 Hz, 1 H, Ph), 7.53–7.63 (m, 1 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 41.2 (1
C, CH2), 52.1 (1 C, OCH3), 67.1 (1 C, (Ph)CH2O), 113.4 (1 C, Ph), 116.0 (1 C, Ph), 122.1 (1 C, Ph), 126.9
(1 C, Ph), 128.8 (1 C, Ph), 129.0 (1 C, Ph), 129.3 (1 C, Ph), 129.6 (1 C, Ph), 132.6 (1 C, Ph), 134.7 (1 C, Ph),
135.5 (1 C, Ph), 158.7 (1 C, Ph), 171.8 (1 C, CO). Then, 13b (0.20 g, 0.69 mmol) was treated with LiAlH4
(52 mg, 1.4 mmol) in dry THF (4.1 mL) to give alcohol intermediate, which was oxidized with PCC
(0.25 g, 1.2 mmol) in DCM (6.0 mL) to yield aldehyde 15b (C15H13ClO2, 0.14 g, 0.53 mmol).
2-(3-((3,4-Dichlorobenzyl)oxy)phenyl)acetaldehyde (15c). Following the procedure as described for 15a,
methyl 2-(3-hydroxyphenyl)acetate (0.40 g, 2.9 mmol), 3,4-dichlorobenzyl bromide (0.70 g, 2.9 mmol),
K2CO3 (0.81 g, 5.9 mmol), sodium iodide (44 mg, 0.29 mmol) in DMF (13 mL) afforded the ester
intermediate methyl 2-(3-((3,4-dichlorobenzyl)oxy)phenyl)acetate 13c (eluent system: 10% ethylacetate
in petroleum ether, C16H14Cl2O3, 0.75 g, 2.3 mmol, 84% yield). 1H NMR (300 MHz, CDCl3) δ ppm 3.62
(s, 2 H, CH2), 3.70 (s, 3 H, OCH3), 5.01 (s, 2 H, (Ph)CH2O), 6.87 (d, J = 8.2 Hz, 1 H, Ph), 6.93 (br. s., 2 H,
Ph), 7.21–7.30 (m, 2 H, Ph), 7.41–7.48 (m, 1 H, Ph), 7.54 (s, 1 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm
41.1 (1 C, CH2), 52.1 (1 C, OCH3), 68.4 (1 C, (Ph)CH2O), 113.4 (1 C, Ph), 115.8 (1 C, Ph), 122.3 (1 C, Ph),
126.5 (1 C, Ph), 129.2 (1 C, Ph), 129.7 (1 C, Ph), 130.5 (1 C, Ph), 131.8 (1 C, Ph), 132.6 (1 C, Ph), 135.6 (1 C,
Ph), 137.3 (1 C, Ph), 158.4 (1 C, Ph), 171.7 (1 C, CO). Then, 13c (0.20 g, 0.62 mmol) was treated with
LiAlH4 (47 mg, 1.2 mmol) in dry THF (3.7 mL) to give alcohol intermediate, which was oxidized with
PCC (0.26 g, 1.2 mmol) in DCM (6.0 mL) to yield aldehyde 15c (C15H12Cl2O2, 0.18 g, 0.60 mmol).
2-(3-((3-Chlorobenzyl)oxy)phenyl)acetaldehyde (15d). Following the procedure as described for 15a, methyl
2-(3-hydroxyphenyl)acetate (0.40 g, 2.9 mmol), m-chlorobenzyl bromide (0.60 g, 2.9 mmol), K2CO3
(0.81 g, 5.9 mmol), sodium iodide (44 mg, 0.29 mmol) in DMF (13 mL) afforded the ester intermediate
methyl 2-(3-((3-chlorobenzyl)oxy)phenyl)acetate 13d (eluent system: 10% ethylacetate in petroleum
ether, C16H15ClO3, 0.62 g, 2.1 mmol, 73% yield). 1H NMR (400 MHz, CDCl3) δ ppm 3.61 (s, 2 H, CH2),
3.70 (s, 3 H, OCH3), 5.03 (s, 2 H, (Ph)CH2O), 6.84–6.94 (m, 3 H, Ph), 7.23–7.28 (m, 1 H, Ph), 7.29–7.32 (m,
3 H, Ph), 7.35–7.48 (m, 1 H, Ph). 13C NMR (101 MHz, CDCl3) δ ppm 41.2 (1 C, CH2), 52.1 (1 C, OCH3),
69.1 (1 C, (Ph)CH2O), 113.4 (1 C, Ph), 115.8 (1 C, Ph), 122.1 (1 C, Ph), 125.3 (1 C, Ph), 127.4 (1 C, Ph),
128.0 (1 C, Ph), 129.6 (1 C, Ph), 129.8 (1 C, Ph), 134.5 (1 C, Ph), 135.5 (1 C, Ph), 139.0 (1 C, Ph), 158.6 (1 C,
Ph), 171.9 (1 C, CO). Then, 13d (0.20 g, 0.69 mmol) was treated with LiAlH4 (52 mg, 1.4 mmol) in dry
THF (4.1 mL) to give alcohol intermediate, which was oxidized with PCC (0.26 g, 1.2 mmol) in DCM
(6.0 mL) to yield aldehyde 15d (C15H13ClO2, 0.14 g, 0.52 mmol).
2-(3-(4-Cyanophenoxy)phenyl)acetaldehyde (18a). To a solution of methyl 2-(3-hydroxyphenyl)acetate (0.35 g,
2.1 mmol) in THF (13 mL) was added LiAlH4 (0.16 g, 4.2 mmol) afforded 3-(2-hydroxyethyl)phenol
(0.24 g, 1.4 mmol), which was reacted with 4-fluorobenzonitrile (0.21 g, 1.7 mmol), K2CO3 (0.40 g,
2.9 mmol) in DMF (10 mL) at 90 ◦C gave 4-(3-(2-hydroxyethyl)phenoxy)benzonitrile [28] 17a (eluent
system: 25% ethylacetate in petroleum ether, C15H13NO2, 0.14 g, 0.59 mmol, 40% yield). 1H NMR
(300 MHz, CDCl3) δppm 2.89 (t, J = 6.6 Hz, 2 H, CH2), 3.89 (t, J = 6.4 Hz, 2 H, CH2(OH)), 6.89–7.06 (m, 4
H, Ph), 7.11 (dd, J = 7.6, 0.59 Hz, 1 H, Ph), 7.36 (t, J = 7.4 Hz, 1 H, Ph), 7.49–7.69 (m, 2 H, Ph). 13C NMR
(75 MHz, CDCl3) δppm 38.9 (1 C, CH2), 63.3 (1 C, CH2(OH)), 105.8 (1 C, Ph), 110.0 (1 C, Ph), 118.0 (2 C,
Ph), 118.3 (1 C, CN), 120.9 (1 C, Ph), 125.7 (1 C, Ph), 130.2 (1 C, Ph), 134.1 (2 C, Ph), 141.4 (1 C, Ph), 154.9
(1 C, Ph), 161.5 (1 C, Ph). Then, 17a was oxidized by PCC (0.25 g, 1.2 mmol) in DCM (6.0 mL) to give
aldehyde 18a (C15H11NO2, 0.11 g, 0.44 mmol).
2-(3-(4-Nitrophenoxy)phenyl)acetaldehyde (18b). Following the procedure described for 18a,
3-(2-hydroxyethyl)phenol (0.30 g, 2.2 mmol), 1-fluoro-4-nitrobenzene (0.37 g, 2.6 mmol) and K2CO3
(0.60 g, 4.3 mmol) in DMF (16 mL) afforded 2-(3-(4-nitrophenoxy)phenyl)ethan-1-ol 17b (eluent system:
25% ethylacetate in petroleum ether, C14H13NO4, 0.52 g, 2.0 mmol, 92% yield). 1H NMR (300 MHz,
CDCl3) δ ppm 2.90 (t, J = 6.4 Hz, 2 H, CH2), 3.89 (t, J = 6.4 Hz, 2 H, CH2(OH)), 6.93–7.07 (m, 4 H, Ph),
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7.13 (d, J = 7.6 Hz, 1 H, Ph), 7.37 (t, J = 7.7 Hz, 1 H, Ph), 8.13–8.24 (m, 2 H, Ph). 13C NMR (75 MHz,
CDCl3) δ ppm 38.8 (1 C, CH2), 63.2 (1 C, CH2(OH)), 117.1 (2 C, Ph), 118.4 (1 C, Ph), 121.0 (1 C, Ph),
125.9 (2 C, Ph), 126.0 (1 C, Ph), 130.3 (1 C, Ph), 136.5 (1 C, Ph), 141.5 (1 C, Ph), 154.9 (1 C, Ph), 163.2
(1 C, Ph). Then, 17b was oxidized by PCC (0.86 g, 4.0 mmol) in DCM (20 mL) to give aldehyde 18b
(C14H11NO4, 0.36 g, 1.4 mmol).
2-(3-(4-(Trifluoromethyl)phenoxy)phenyl)acetaldehyde (18c). Following the procedure described
for 18a, 3-(2-hydroxyethyl)phenol (0.30 g, 2.2 mmol), 1-fluoro-4-(trifluoromethyl)benzene
(0.43 g, 2.6 mmol) and CsCO3 (0.85 g, 2.6 mmol) in DMF (16 mL) at 90 ◦C gave
2-(3-(4-(trifluoromethyl)phenoxy)phenyl)ethan-1-ol 17c (eluent system: 25% ethylacetate in petroleum
ether, C15H13F3O2, 0.13 g, 0.46 mmol, 21% yield). 1H NMR (300 MHz, CDCl3) δ ppm 2.87 (t, J = 6.6 Hz,
2 H, CH2), 3.86 (t, J = 6.6 Hz, 2 H, CH2(OH)), 6.89–6.98 (m, 2 H, Ph), 7.01–7.12 (m, 3 H, Ph), 7.33 (t,
J = 6.6 Hz, 1 H, Ph), 7.58 (d, J = 8.8 Hz, 2 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 38.9 (1 C, CH2),
63.3 (1 C, CH2(OH)), 117.7 (1 C, Ph), 117.8 (2 C, Ph), 120.4 (2 C, Ph), 124.2 (q, J = 271.5 Hz, 1 C, CF3),
125.1 (1 C, Ph), 127.0 (2 C, Ph), 130.0 (1 C, Ph), 141.1 (1 C, Ph), 155.9 (1 C, Ph), 160.3 (1 C, Ph). Then, 17c
was oxidized by PCC (0.20 g, 0.92 mmol) in DCM (4.6 mL) to give aldehyde 18c (C15H11F3O2, 0.12 g,
0.43 mmol).
5-Methyl-1-(1-phenethylpiperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (21a). Following the general procedure
B, phenylacetaldehyde (36 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride
(0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was
deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21a
(eluent system: 5% MeOH in DCM, 53 mg, 0.17 mmol, 56% yield). 1H NMR (300 MHz, DMSO-d6)
δ ppm 1.53–1.93 (m, 7 H, 5-CH3, piperdyl-3-yl, piperidyl-5-yl), 2.00–2.16 (m, 2 H, piperidyl-2a-yl,
piperidyl-6a-yl), 2.57 (d, J = 8.2 Hz, 2 H, CH2N), 2.66–2.82 (m, 2 H, PhCH2), 3.06 (d, J = 10.8 Hz, 2 H,
piperidyl-2b-yl, piperidyl-6b-yl), 4.16–4.36 (m, 1 H, piperidyl-4-yl), 7.10–7.37 (m, 5 H, Ph), 7.63 (s, 1 H,
H-6), 11.19 (s, 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 29.9 (2 C, piperdyl-3-yl,
piperidyl-5-yl), 33.0 (1 C, PhCH2), 52.4 (2 C, piperidyl-2-yl, piperidyl-6-yl), 52.6 (1 C, piperidyl-4-yl),
59.3 (1 C, CH2N), 108.9 (1 C, C-5), 125.8 (1 C, Ph), 128.2 (2 C, Ph), 128.6 (2 C, Ph), 137.7 (1 C, C-6), 140.4
(1 C, Ph), 150.8 (1 C, C-2), 163.7 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C18H23N3O2 + H]+
314.1863, found 314.1855.
1-(1-(2-([1,1’-Biphenyl]-4-yl)ethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21b). Following
the general procedure B, 6 (60 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride
(0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was
deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21b
(eluent system: 5% MeOH in DCM, 39 mg, 0.10 mmol, 33% yield). 1H NMR (400 MHz, DMSO-d6)
δ ppm 1.72–1.93 (m, 5 H, piperdyl-3a-yl, piperidyl-5a-yl, 5-CH3), 1.98–2.20 (m, 2 H, piperdyl-3b-yl,
piperidyl-5b-yl), 2.89–3.04 (m, 2 H, PhCH2), 3.26–3.61 (m, 4 H, piperidyl-2-yl, piperidyl-6-yl), 4.39–4.53
(m, 1 H, piperidyl-4-yl), 7.33–7.40 (m, 3 H, Ph), 7.46 (t, J = 7.6 Hz, 2 H, Ph), 7.59–7.71 (m, 5 H, H-6,
Ph), 11.30 (s, 1 H, NH), 2 H (CH2N) could not be observed. 13C NMR (101 MHz, DMSO-d6) δ ppm
12.1 (1 C, 5-CH3), 27.7 (2 C, piperdyl-3-yl, piperidyl-5-yl), 29.9 (1 C, PhCH2), 51.4 (3 C, piperidyl-2-yl,
piperidyl-6-yl, piperidyl-4-yl), 109.1 (1 C, C-5), 126.6 (2 C, Ph), 126.8 (2 C, Ph), 127.4 (1 C, Ph), 128.9
(2 C, Ph), 129.3 (2 C, Ph), 137.5 (3 C, C-6, Ph), 139.9 (1 C, Ph), 150.8 (1 C, C-2), 163.7 (1 C, C-4), C (CH2N)
could not be observed. HRMS (ESI): m/z [M + H]+ Calcd. for [C24H27N3O2 + H]+ 390.2176, found
390.2186.
5-Methyl-1-(1-(2-phenoxyphenethyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (21c). Following the general
procedure B, 12a (64 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride (0.13 g,
0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was deprotected
with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21c (eluent system:
5% MeOH in DCM, 40 mg, 0.098 mmol, 32% yield). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.52–1.62
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(m, 2 H, piperdyl-3a-yl, piperidyl-5a-yl), 1.68–1.84 (m, 5 H, 5-CH3, piperdyl-3b-yl, piperidyl-5b-yl),
1.92–2.04 (m, 2 H, piperidyl-2a-yl, piperidyl-6a-yl), 2.50–2.55 (m, 2 H, CH2N), 2.64–2.75 (m, 2 H, PhCH2),
2.92 (d, J = 11.1 Hz, 2 H, piperidyl-2b-yl, piperidyl-6b-yl), 4.12–4.26 (m, 1 H, piperidyl-4-yl), 6.85–6.92
(m, 3 H, Ph), 7.02–7.15 (m, 2 H, Ph), 7.17–7.26 (m, 1 H, Ph), 7.29–7.38 (m, 3 H, Ph), 7.57 (d, J = 1.2 Hz, 1 H,
H-6), 11.16 (s, 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 27.3 (1 C, PhCH2), 29.9
(2 C, piperdyl-3-yl, piperidyl-5-yl), 52.3 (2 C, piperidyl-2-yl, piperidyl-6-yl), 52.3 (1 C, piperidyl-4-yl),
57.9 (1 C, CH2N), 108.9 (1 C, C-5), 117.1 (2 C, Ph), 119.8 (1 C, Ph), 122.6 (1 C, Ph), 124.2 (1 C, Ph), 127.7
(1 C, Ph), 129.9 (2 C, Ph), 131.1 (1 C, Ph), 131.8 (1 C, Ph), 137.6 (1 C, C-6), 150.8 (1 C, C-2), 153.8 (1 C, Ph),
157.6 (1 C, Ph), 163.6 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C24H27N3O3 + H]+ 406.2125,
found 406.2133.
5-Methyl-1-(1-(4-phenoxyphenethyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (21e). Following the general
procedure B, 12c (64 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride (0.13 g,
0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was deprotected
with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21e (eluent system:
5% MeOH in DCM, 65 mg, 0.16 mmol, 53% yield). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.57–1.93
(m, 7 H, 5-CH3, piperdyl-3-yl, piperidyl-5-yl), 1.97–2.16 (m, 2 H, piperidyl-2a-yl, piperidyl-6a-yl),
2.54 (d, J = 7.3 Hz, 2 H, CH2N), 2.64–2.77 (m, 2 H, PhCH2), 3.04 (d, J = 11.1 Hz, 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 4.19–4.29 (m, 1 H, piperidyl-4-yl), 6.87–6.98 (m, 4 H, Ph), 7.04–7.13 (m, 1 H, Ph),
7.18–7.26 (m, 2 H, Ph), 7.29–7.41 (m, 2 H, Ph), 7.60 (d, J = 0.9 Hz, 1 H, H-6), 11.17 (s, 1 H, NH). 13C
NMR (75 MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 29.9 (2 C, piperdyl-3-yl, piperidyl-5-yl), 32.2 (1 C,
PhCH2), 52.4 (2 C, piperidyl-2-yl, piperidyl-6-yl), 52.6 (1 C, piperidyl-4-yl), 59.3 (1 C, CH2N), 108.9
(1 C, C-5), 118.2 (2 C, Ph), 118.7 (2 C, Ph), 123.1 (1 C, Ph), 130.0 (2 C, Ph), 130.1 (2 C, Ph), 135.6 (1 C, Ph),
137.7 (1 C, C-6), 150.8 (1 C, C-2), 154.6 (1 C, Ph), 157.0 (1 C, Ph), 163.7 (1 C, C-4). HRMS (ESI): m/z [M +
H]+ Calcd. for [C24H27N3O3 + H]+ 406.2125, found 406.2124.
5-Methyl-1-(1-(3-(p-tolyloxy)phenethyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (21f). Following the
general procedure B, 12d (69 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride
(0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was
deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21f
(eluent system: 5% MeOH in DCM, 40 mg, 0.095 mmol, 31% yield). 1H NMR (400 MHz, DMSO-d6) δ
ppm 1.64 (d, J = 10.6 Hz, 2 H, piperdyl-3a-yl, piperidyl-5a-yl), 1.73 - 1.87 (m, 5 H, 5-CH3, piperdyl-3b-yl,
piperidyl-5b-yl), 2.05 (t, J = 11.1 Hz, 2 H, piperidyl-2a-yl, piperidyl-6a-yl), 2.28 (s, 3 H, PhCH3), 2.54
(d, J = 8.4 Hz, 2 H, CH2N), 2.72 (t, J = 7.5 Hz, 2 H, PhCH2), 3.02 (d, J = 11.5 Hz, 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 4.19–4.29 (m, 1 H, piperidyl-4-yl), 6.77 (d, J = 8.1 Hz, 1 H, Ph), 6.87 (s, 1 H, Ph), 6.90 (d,
J = 8.3 Hz, 2 H, Ph), 6.98 (d, J = 7.6 Hz, 1 H, Ph), 7.19 (d, J = 8.4 Hz, 2 H, Ph), 7.26 (t, J = 7.8 Hz, 1 H,
Ph), 7.61 (s, 1 H, H-6), 11.20 (s, 1 H, NH). 13C NMR (101 MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3),
20.2 (1 C, PhCH3), 30.0 (2 C, piperdyl-3-yl, piperidyl-5-yl), 32.8 (1 C, PhCH2), 52.4 (2 C, piperidyl-2-yl,
piperidyl-6-yl), 52.5 (1 C, piperidyl-4-yl), 59.0 (1 C, CH2N), 108.9 (1 C, C-5), 115.5 (1 C, Ph), 118.4 (1 C,
Ph), 118.8 (2 C, Ph), 123.4 (1 C, Ph), 129.7 (1 C, Ph), 130.3 (2 C, Ph), 132.5 (1 C, Ph), 137.7 (1 C, C-6), 142.7
(1 C, Ph), 150.8 (1 C, C-2), 154.2 (1 C, Ph), 157.1 (1 C, Ph), 163.7 (1 C, C-4). HRMS (ESI): m/z [M + H]+
Calcd. for [C25H29N3O3 + H]+ 420.2282, found 420.2286.
1-(1-(3-(3,4-Dichlorophenoxy)phenethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21g).
Following the general procedure B, 12e (85 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium
triacetoxyborohydride (0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected
intermediate, which was deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at
73 ◦C for 4 h to give the 21g (eluent system: 5% MeOH in DCM, 56 mg, 0.12 mmol, 39% yield). 1H NMR
(400 MHz, DMSO-d6) δ ppm 1.79 (s, 3 H, 5-CH3), 1.91–2.06 (m, 2 H, piperdyl-3a-yl, piperidyl-5a-yl),
2.10–2.19 (m, 2 H, piperdyl-3b-yl, piperidyl-5b-yl), 2.96–3.08 (m, 2 H, PhCH2), 3.09–3.22 (m, 2 H,
piperidyl-2a-yl, piperidyl-6a-yl), 3.25–3.37 (m, 2 H, CH2N), 3.56–3.73 (m, 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 4.46–4.59 (m, 1 H, piperidyl-4-yl), 7.02 (dd, J = 8.9, 2.9 Hz, 2 H, Ph), 7.06 (br. s., 1
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H, Ph), 7.15 (d, J = 7.3 Hz, 1 H, Ph), 7.30 (d, J = 2.8 Hz, 1 H, Ph), 7.34–7.46 (m, 2 H, H-6, Ph), 7.65 (d,
J = 8.9 Hz, 1 H, Ph), 11.34 (s, 1 H, NH). 13C NMR (101 MHz, DMSO-d6) δ ppm 12.2 (1 C, 5-CH3), 27.1 (2
C, piperdyl-3-yl, piperidyl-5-yl), 29.4 (1 C, PhCH2), 50.5 (1 C, piperidyl-4-yl), 51.2 (2 C, piperidyl-2-yl,
piperidyl-6-yl), 56.3 (1 C, CH2N), 109.3 (1 C, C-5), 117.8 (1 C, Ph), 118.7 (1 C, Ph), 119.5 (1 C, Ph), 120.2
(1 C, Ph), 125.16 (d, J = 43.5 Hz, 1 C, Ph), 130.6 (1 C, Ph), 131.6 (2 C, Ph), 132.0 (1 C, Ph), 137.4 (1 C, C-6),
139.6 (1 C, Ph), 150.7 (1 C, C-2), 155.8 (1 C, Ph), 156.4 (1 C, Ph), 163.7 (1 C, C-4). HRMS (ESI): m/z [M +
H]+ Calcd. for [C24H25Cl2N3O3 + H]+ 474.1346, found 474.1333.
1-(1-(3-(4-Chlorophenoxy)phenethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21h). Following
the general procedure B, 12f (75 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium
triacetoxyborohydride (0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected
intermediate, which was deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at
73 ◦C for 4 h to give the 21h (eluent system: 5% MeOH in DCM, 40 mg, 0.091 mmol, 30% yield). 1H
NMR (300 MHz, DMSO-d6) δ ppm 1.57–1.67 (m, 2 H, piperdyl-3a-yl, piperidyl-5a-yl), 1.68–1.87 (m, 5
H, 5-CH3, piperdyl-3b-yl, piperidyl-5b-yl), 2.03 (t, J = 12.3 Hz, 2 H, piperidyl-2a-yl, piperidyl-6a-yl),
2.54 (d, J = 8.5 Hz, 2 H, CH2N), 2.72 (t, J = 7.4 Hz, 2 H, PhCH2), 3.00 (d, J = 12.0 Hz, 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 4.22 (tt, J = 12.1, 4.5 Hz, 1 H, piperidyl-4-yl), 6.83 (dd, J = 7.8, 1.9 Hz, 1 H, Ph), 6.92
(s, 1 H, Ph), 6.96–7.06 (m, 3 H, Ph), 7.24–7.33 (m, 1 H, Ph), 7.38–7.43 (m, 2 H, Ph), 7.59 (s, 1 H, H-6),
11.17 (s, 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 30.0 (2 C, piperdyl-3-yl,
piperidyl-5-yl), 32.7 (1 C, PhCH2), 52.4 (2 C, piperidyl-2-yl, piperidyl-6-yl), 52.5 (1 C, piperidyl-4-yl),
59.0 (1 C, CH2N), 108.9 (1 C, C-5), 116.3 (1 C, Ph), 119.2 (1 C, Ph), 120.0 (2 C, Ph), 124.3 (1 C, Ph), 126.9
(1 C, Ph), 129.8 (2 C, Ph), 129.9 (1 C, Ph), 137.6 (1 C, C-6), 143.0 (1 C, Ph), 150.8 (1 C, C-2), 155.8 (1 C, Ph),
156.1 (1 C, Ph), 163.7 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C24H26ClN3O3 + H]+ 440.1736,
found 440.1750.
1-(1-(3-(4-Methoxyphenoxy)phenethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21i). Following
the general procedure B, 12g (74 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium
triacetoxyborohydride (0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected
intermediate, which was deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at
73 ◦C for 4 h to give the 21i (eluent system: 5% MeOH in DCM, 40 mg, 0.092 mmol, 30% yield). 1H NMR
(400 MHz, DMSO-d6) δ ppm 1.65 (d, J = 10.6 Hz, 2 H, piperdyl-3a-yl, piperidyl-5a-yl), 1.74–1.87 (m, 5
H, piperdyl-3b-yl, piperidyl-5b-yl, 5-CH3), 2.05 (t, J = 11.3 Hz, 2 H, piperidyl-2a-yl, piperidyl-6a-yl),
2.52–2.56 (m, 2 H, CH2N), 2.70 (t, J = 8.3 Hz, 2 H, PhCH2), 3.02 (d, J = 11.4 Hz, 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 3.74 (s, 3 H, OCH3), 4.19–4.29 (m, 1 H, piperidyl-4-yl), 6.72 (d, J = 8.1 Hz, 1 H, Ph),
6.83 (s, 1 H, Ph), 6.92–7.01 (m, 5 H, Ph), 7.24 (t, J = 7.9 Hz, 1 H, Ph), 7.61 (s, 1 H, H-6), 11.20 (s, 1 H, NH).
13C NMR (101 MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 30.0 (2 C, piperdyl-3-yl, piperidyl-5-yl), 32.8
(1 C, PhCH2), 52.4 (2 C, piperidyl-2-yl, piperidyl-6-yl), 52.5 (1 C, piperidyl-4-yl), 55.4 (1 C, OCH3), 59.0
(1 C, CH2N), 108.9 (1 C, C-5), 114.7 (1 C, Ph), 115.0 (2 C, Ph), 117.6 (1 C, Ph), 120.6 (2 C, Ph), 123.0 (1 C,
Ph), 129.6 (1 C, Ph), 137.7 (1 C, C-6), 142.6 (1 C, Ph), 149.4 (1 C, Ph), 150.8 (1 C, C-2), 155.5 (1 C, Ph),
157.9 (1 C, Ph), 163.7 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C25H29N3O4 + H]+ 436.2231,
found 436.2234.
1-(1-(3-(3-Chlorophenoxy)phenethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21j). Following
the general procedure B, 12h (75 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium
triacetoxyborohydride (0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected
intermediate, which was deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at
73 ◦C for 4 h to give the 21j (eluent system: 5% MeOH in DCM, 63 mg, 0.14 mmol, 47% yield). 1H NMR
(400 MHz, DMSO-d6) δ ppm 1.65 (d, J = 9.8 Hz, 2 H, piperdyl-3a-yl, piperidyl-5a-yl), 1.71–1.89 (m,
5 H, piperdyl-3b-yl, piperidyl-5b-yl, 5-CH3), 2.06 (t, J = 11.0 Hz, 2 H, piperidyl-2a-yl, piperidyl-6a-yl),
2.53–2.62 (m, 2 H, CH2N), 2.69–2.79 (m, 2 H, PhCH2), 3.03 (d, J = 11.6 Hz, 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 4.17–4.31 (m, 1 H, piperidyl-4-yl), 6.88 (dd, J = 8.1, 1.8 Hz, 1 H, Ph), 6.92–7.00 (m, 2 H,
Ph), 7.02 (t, J = 2.2 Hz, 1 H, Ph), 7.08 (d, J = 7.8 Hz, 1 H, Ph), 7.15–7.21 (m, 1 H, Ph), 7.33 (t, J = 7.8 Hz, 1
Molecules 2020, 25, 2805 16 of 21
H, Ph), 7.37–7.43 (m, 1 H, Ph), 7.60 (d, J = 0.9 Hz, 1 H, H-6), 11.20 (s, 1 H, NH). 13C NMR (101 MHz,
DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 30.0 (2 C, piperdyl-3-yl, piperidyl-5-yl), 32.7 (1 C, PhCH2), 52.4
(3 C, piperidyl-2-yl, piperidyl-6-yl, piperidyl-4-yl), 58.9 (1 C, CH2N), 108.9 (1 C, C-5), 116.7 (1 C, Ph),
116.8 (1 C, Ph), 118.0 (1 C, Ph), 119.6 (1 C, Ph), 123.0 (1 C, Ph), 124.7 (1 C, Ph), 130.0 (1 C, Ph), 131.4 (1 C,
Ph), 133.9 (1 C, Ph), 137.6 (1 C, C-6), 143.1 (1 C, Ph), 150.8 (1 C, C-2), 155.5 (1 C, Ph), 158.1 (1 C, Ph),
163.7 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C24H26ClN3O3 + H]+ 440.1736, found 440.1740.
4-(3-(2-(4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1- yl)ethyl)phenoxy)benzonitrile (21k).
Following the general procedure B, 18a (72 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium
triacetoxyborohydride (0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected
intermediate, which was deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL)
at 73 ◦C for 4 h to give the 21k (eluent system: 5% MeOH in DCM, 50 mg, 0.12 mmol, 43% yield).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.79 (s, 3 H, 5-CH3), 2.00 (d, J = 10.8 Hz, 2 H, piperdyl-3a-yl,
piperidyl-5a-yl), 2.21 (d, J = 11.6 Hz, 2 H, piperdyl-3b-yl, piperidyl-5b-yl), 3.05 (br. s., 2 H, PhCH2),
3.15 (br. s., 2 H, piperidyl-2a-yl, piperidyl-6a-yl), 3.32 (s, 2 H, CH2N), 3.66 (br. s., 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 4.44–4.63 (m, 1 H, piperidyl-4-yl), 7.03–7.16 (m, 4 H, Ph), 7.21 (d, J = 6.6 Hz, 1 H, Ph),
7.35–7.53 (m, 2 H, Ph, H-6), 7.86 (d, J = 8.4 Hz, 2 H, Ph), 11.32 (br. s., 1 H, NH). 13C NMR (101 MHz,
DMSO-d6) δ ppm 12.2 (1 C, 5-CH3), 27.1 (2 C, piperdyl-3-yl, piperidyl-5-yl), 29.3 (1 C, PhCH2), 50.3 (1
C, piperidyl-4-yl), 51.2 (2 C, piperidyl-2-yl, piperidyl-6-yl), 56.2 (1 C, CH2N), 105.2 (1 C, Ph), 109.3 (1 C,
C-5), 118.1 (2 C, Ph), 118.7 (2 C, Ph, CN), 120.5 (1 C, Ph), 125.6 (1 C, Ph), 130.7 (1 C, Ph), 134.7 (2 C, Ph),
137.3 (1 C, C-6), 139.7 (1 C, Ph), 150.7 (1 C, C-2), 154.7 (1 C, Ph), 161.0 (1 C, Ph), 163.6 (1 C. C-4). HRMS
(ESI): m/z [M + H]+ Calcd. for [C25H26N4O3 + H]+ 431.2078, found 431.2085.
5-Methyl-1-(1-(3-(4-nitrophenoxy)phenethyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (21l). Following the
general procedure B, 18b (78 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride
(0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was
deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21l
(eluent system: 5% MeOH in DCM, 67 mg, 0.15 mmol, 40% yield). 1H NMR (400 MHz, DMSO-d6)
δ ppm 1.79 (s, 3 H, 5-CH3), 1.93–2.06 (m, 2 H, piperdyl-3a-yl, piperidyl-5a-yl), 2.20 (d, J = 11.6 Hz,
2 H, piperdyl-3b-yl, piperidyl-5b-yl), 2.98–3.08 (m, 2 H, PhCH2), 3.09–3.24 (m, 2 H, piperidyl-2a-yl,
piperidyl-6a-yl), 3.41–3.55 (m, 2 H, CH2N), 3.67 (d, J = 10.6 Hz, 2 H, piperidyl-2b-yl, piperidyl-6b-yl),
4.44–4.62 (m, 1 H, piperidyl-4-yl), 7.09–7.17 (m, 4 H, Ph), 7.24 (d, J = 7.5 Hz, 1 H, Ph), 7.38 (s, 1 H,
H-6), 7.49 (t, J = 7.8 Hz, 1 H, Ph), 8.27 (d, J = 9.1 Hz, 2 H, Ph), 11.32 (s, 1 H, NH). 13C NMR (101 MHz,
DMSO-d6) δ ppm 12.2 (1 C, 5-CH3), 27.0 (2 C, piperdyl-3-yl, piperidyl-5-yl), 29.3 (1 C, PhCH2), 50.5
(1 C, piperidyl-4-yl), 51.2 (2 C, piperidyl-2-yl, piperidyl-6-yl), 56.2 (1 C, CH2N), 109.3 (1 C, C-5), 117.5
(2 C, Ph), 118.9 (1 C, Ph), 120.7 (1 C, Ph), 125.9 (1 C, Ph), 126.2 (2 C, Ph), 130.8 (1 C, Ph), 137.3 (1 C, C-6),
139.4 (1 C, Ph), 142.3 (1 C, Ph), 150.7 (1 C, C-2), 154.5 (1 C, Ph), 162.7 (1 C, Ph), 163.6 (1 C, C-4). HRMS
(ESI): m/z [M + H]+ Calcd. for [C24H26N4O5 + H]+ 451.1976, found 451.1971.
5-Methyl-1-(1-(3-(4-(trifluoromethyl)phenoxy)phenethyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (21m).
Following the general procedure B, 18c (85 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium
triacetoxyborohydride (0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected
intermediate, which was deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL)
at 73 ◦C for 4 h to give the 21m (eluent system: 5% MeOH in DCM, 64 mg, 0.14 mmol, 44% yield).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.79 (s, 3 H, 5-CH3), 2.00 (d, J = 12.0 Hz, 2 H, piperdyl-3a-yl,
piperidyl-5a-yl), 2.20 (d, J = 11.4 Hz, 2 H, piperdyl-3b-yl, piperidyl-5b-yl), 2.99 - 3.08 (m, 2 H, PhCH2),
3.16 (d, J = 9.5 Hz, 2 H, piperidyl-2a-yl, piperidyl-6a-yl), 3.39–3.55 (m, 2 H, CH2N), 3.67 (d, J = 10.6
Hz, 2 H, piperidyl-2b-yl, piperidyl-6b-yl), 4.47–4.59 (m, 1 H, piperidyl-4-yl), 7.05 (d, J = 7.9 Hz, 1 H,
Ph), 7.10–7.20 (m, 4 H, Ph), 7.39 (br. s., 1 H, H-6), 7.44 (t, J = 7.8 Hz, 1 H, Ph), 7.75 (d, J = 8.5 Hz, 2 H,
Ph), 11.32 (s, 1 H, NH). 19F NMR (377 MHz, DMSO-d6) δ ppm -60.16 (s, 3 F). 13C NMR (101 MHz,
DMSO-d6) δ ppm 12.2 (1 C, 5-CH3), 27.1 (2 C, piperdyl-3-yl, piperidyl-5-yl), 29.3 (1 C, PhCH2), 50.4 (1
C, piperidyl-4-yl), 51.1 (2 C, piperidyl-2-yl, piperidyl-6-yl), 56.3 (1 C, CH2N), 109.3 (1 C, C-5), 118.0 (2
Molecules 2020, 25, 2805 17 of 21
C, Ph), 118.4 (1 C, Ph), 120.2 (1 C, Ph), 123.20 (q, J = 32.6 Hz, 1 C, Ph), 124.27 (q, J = 271.3 Hz, 1 C, CF3),
125.2 (1 C, Ph), 127.5 (2 C, Ph), 130.6 (1 C, Ph), 137.3 (1 C, C-6), 139.6 (1 C, Ph), 150.7 (1 C, C-2), 155.2
(1 C, Ph), 160.3 (1 C, Ph), 163.6 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C25H26F3N3O3 + H]+
474.1999, found 474.1989.
1-(1-(3-(Benzyloxy)phenethyl)piperidin-4-yl)-5-methylpyridine-2,4(1H,3H)-dione (21n). Following the
general procedure B, 15a (69 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride
(0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was
deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21n
(eluent system: 5% MeOH in DCM, 58 mg, 0.14 mmol, 46% yield). 1H NMR (400 MHz, DMSO-d6) δ
ppm 1.66 (d, J = 10.8 Hz, 2 H, piperdyl-3a-yl, piperidyl-5a-yl), 1.74–1.90 (m, 5 H, 5-CH3, piperdyl-3b-yl,
piperidyl-5b-yl), 2.07 (t, J = 11.3 Hz, 2 H, piperidyl-2a-yl, piperidyl-6a-yl), 2.55 (t, J = 9.0 Hz, 2 H,
CH2N), 2.70 (t, J = 7.4 Hz, 2 H, PhCH2), 3.04 (d, J = 11.3 Hz, 2 H, piperidyl-2b-yl, piperidyl-6b-yl),
4.20–4.31 (m, 1 H, piperidyl-4-yl), 5.08 (s, 2 H, (Ph)CH2O), 6.82 (t, J = 7.8 Hz, 2 H, Ph), 6.90 (s, 1 H, Ph),
7.19 (t, J = 7.9 Hz, 1 H, Ph), 7.30–7.35 (m, 1 H, Ph), 7.39 (t, J = 7.4 Hz, 2 H, Ph), 7.43–7.48 (m, 2 H, Ph),
7.63 (s, 1 H, H-6), 11.20 (s, 1 H, NH).13C NMR (101 MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 30.0 (2 C,
piperdyl-3-yl, piperidyl-5-yl), 33.0 (1 C, PhCH2), 52.4 (2 C, piperidyl-2-yl, piperidyl-6-yl), 52.4 (1 C,
piperidyl-4-yl), 59.2 (1 C, CH2N), 69.0 (1 C, (Ph)CH2O), 108.9 (1 C, C-5), 112.1 (1 C, Ph), 115.2 (1 C, Ph),
121.1 (1 C, Ph), 127.7 (2 C, Ph), 127.8 (1 C, Ph), 128.4 (2 C, Ph), 129.2 (1 C, Ph), 137.2 (1 C, Ph), 137.7 (1 C,
C-6), 142.0 (1 C, Ph), 150.8 (1 C, C-2), 158.4 (1 C, Ph), 163.7 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd.
for [C25H29N3O3 + H]+ 420.2282, found 420.2277.
1-(1-(3-((2-Chlorobenzyl)oxy)phenethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21o). Following
the general procedure B, 15b (79 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride
(0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was
deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21o
(eluent system: 5% MeOH in DCM, 90 mg, 0.20 mmol, 65% yield). 1H NMR (400 MHz, DMSO-d6) δ
ppm 1.73–2.23 (m, 7 H, piperdyl-3-yl, piperidyl-5-yl, 5-CH3), 2.92 (br. s., 2 H, PhCH2), 3.21–3.67(m, 4 H,
piperidyl-2-yl, piperidyl-6-yl), 4.35–4.68 (m, 1 H, piperidyl-4-yl), 5.12 (s, 2 H, (Ph)CH2O), 6.85–6.93 (m, 2
H, Ph), 6.97 (br. s., 1 H, Ph), 7.26 (t, J = 7.8 Hz, 1 H, Ph), 7.36–7.49 (m, 4 H, Ph), 7.52 (s, 1 H, H-6), 11.31
(br. s., 1 H, NH), 2 H (CH2N) could not be observed. 13C NMR (101 MHz, DMSO-d6) δppm 12.2 (1 C,
5-CH3), 27.0 (2 C, piperdyl-3-yl, piperidyl-5-yl), 30.2 (1 C, PhCH2), 50.4 (1 C, piperidyl-4-yl), 51.5 (2 C,
piperidyl-2-yl, piperidyl-6-yl), 68.2 (1 C, (Ph)CH2O), 109.2 (1 C, C-5), 112.7 (1 C, Ph), 115.6 (1 C, Ph), 121.4
(1 C, Ph), 126.2 (2 C, Ph), 127.3 (1 C, Ph), 127.8 (1 C, Ph), 129.7 (1 C, Ph), 130.4 (1 C, Ph), 133.1 (1 C, Ph),
137.5 (1 C, C-6), 139.7 (1 C, Ph), 150,8 (1 C, C-2), 158.3 (1 C, Ph), 163.7 (1 C, C-4), C (CH2N) could not be
observed. HRMS (ESI): m/z [M + H]+ Calcd. for [C25H28ClN3O3 + H]+ 454.1892, found 454.1902.
1-(1-(3-((3,4-Dichlorobenzyl)oxy)phenethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21p).
Following the general procedure B, 15c (90 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium
triacetoxyborohydride (0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected
intermediate, which was deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at
73 ◦C for 4 h to give the 21p (eluent system: 5% MeOH in DCM, 55 mg, 0.11 mmol, 37% yield). 1H NMR
(400 MHz, DMSO-d6) δ ppm 1.79 (s, 3 H, 5-CH3), 1.92–2.06 (m, 2 H, piperdyl-3a-yl, piperidyl-5a-yl),
2.08–2.24 (m, 2 H, piperdyl-3b-yl, piperidyl-5b-yl), 2.85–3.02 (m, 2 H, PhCH2), 3.06–3.22 (m, 2
H, piperidyl-2a-yl, piperidyl-6a-yl), 3.24–3.34 (m, 2 H, CH2N), 3.65 (br. s., 2 H, piperidyl-2b-yl,
piperidyl-6b-yl), 4.45–4.59 (m, 1 H, piperidyl-4-yl), 5.13 (s, 2 H, (Ph)CH2O), 6.85–6.95 (m, 2 H, Ph),
6.98 (br. s., 1 H, Ph), 7.28 (t, J = 7.9 Hz, 1 H, Ph), 7.38–7.48 (m, 2 H, H-6, Ph), 7.68 (d, J = 8.3 Hz, 1 H,
Ph), 7.73 (d, J = 1.5 Hz, 1 H, Ph), 11.33 (s, 1 H, NH). 13C NMR (101 MHz, DMSO-d6) δ ppm 12.2 (1 C,
5-CH3), 27.2 (2 C, piperdyl-3-yl, piperidyl-5-yl), 29.7 (1 C, PhCH2), 50.6 (1 C, piperidyl-4-yl), 51.2 (2 C,
piperidyl-2-yl, piperidyl-6-yl), 56.5 (1 C, CH2N), 67.5 (1 C, (Ph)CH2O), 109.3 (1 C, C-5), 112.8 (1 C, Ph),
115.5 (1 C, Ph), 121.5 (1 C, Ph), 127.8 (1 C, Ph), 129.4 (1 C, Ph), 129.8 (1 C, Ph), 130.4 (1 C, Ph), 130.7 (1 C,
Molecules 2020, 25, 2805 18 of 21
Ph), 131.1 (1 C, Ph), 137.4 (1 C, C-6), 138.3 (2 C, Ph), 150.7 (1 C, C-2), 158.2 (1 C, Ph), 163.7 (1 C, C-4).
HRMS (ESI): m/z [M + H]+ Calcd. for [C25H27Cl2N3O3 + H]+ 488.1502, found 488.1518.
1-(1-(3-((3-Chlorobenzyl)oxy)phenethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (21q). Following
the general procedure B, 15d (79 mg, 0.30 mmol), 28 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride
(0.13 g, 0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was
deprotected with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 21q
(eluent system: 5% MeOH in DCM, 38 mg, 0.084 mmol, 28% yield). 1H NMR (400 MHz, DMSO-d6) δ
ppm 1.78 (s, 5 H, 5-CH3, piperdyl-3a-yl, piperidyl-5a-yl), 2.00 (br. s., 2 H, piperdyl-3b-yl, piperidyl-5b-yl),
2.84 (br. s., 2 H, PhCH2), 4.31–4.46 (m, 1 H, piperidyl-4-yl), 5.12 (s, 2 H, (Ph)CH2O), 6.87 (t, J = 8.3 Hz, 2
H, Ph), 6.94 (br.s., 1 H, Ph), 7.23 (t, J = 7.8 Hz, 1 H, Ph), 7.37–7.47 (m, 3 H, Ph), 7.50–7.59 (m, 2 H, Ph,
H-6), 11.26 (s, 1 H, NH), 2 H (CH2N) and 4 H (piperidyl-2-yl, piperidyl-6-yl) could not be observed. 13C
NMR (101 MHz, DMSO-d6) δppm 12.1 (1 C, 5-CH3), 28.6 (2 C, piperdyl-3-yl, piperidyl-5-yl), 31.3 (1 C,
PhCH2), 51.5 (1 C, piperidyl-4-yl), 51.7 (2 C, piperidyl-2-yl, piperidyl-6-yl), 68.1 (1 C, (Ph)CH2O), 109.0 (1
C, C-5), 112.5 (1 C, Ph), 115.4 (1 C, Ph), 121.3 (1 C, Ph), 126.1 (1 C, Ph), 127.3 (1 C, Ph), 127.7 (1 C, Ph),
129.5 (1 C, Ph), 130.4 (1 C, Ph), 133.1 (1 C, Ph), 137.5 (1 C, C-6), 139.7 (1 C, Ph), 150.8 (1 C, C-2), 158.2 (1 C,
Ph), 163.7 (1 C, C-4), C (CH2N) and C (Ph) could not be observed. HRMS (ESI): m/z [M + H]+ Calcd. for
[C25H28ClN3O3 + H]+ 454.1892, found 454.1899.
5-Methyl-1-(1-(3-phenoxyphenethyl)piperidin-3-yl)pyrimidine-2,4(1H,3H)-dione (23). Following the general
procedure B, 12b (65 mg, 0.30 mmol), 29 (0.10 g, 0.30 mmol) and sodium triacetoxyborohydride (0.13 g,
0.61 mmol) in dichloroethane (10 mL) afforded the BOM-protected intermediate, which was deprotected
with TFA (5.0 mL) in the presence of triethylsilane (5.0 mL) at 73 ◦C for 4 h to give the 23 (eluent system:
5% MeOH in DCM, 57 mg, 0.14 mmol, 46% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.43–1.56 (m,
1 H, piperdyl-5a-yl), 1.59–1.80 (m, 6 H, 5-CH3, piperdyl-4-yl, piperdyl-5b-yl), 2.07 (t, J = 12.9 Hz, 1 H,
piperdyl-6a-yl), 2.22 (t, J = 10.3 Hz, 1 H, piperdyl-2a-yl), 2.56 (t, J = 4.6 Hz, 2 H, CH2N), 2.68–2.81 (m,
3 H, piperdyl-6b-yl, PhCH2), 2.82–2.90 (m, 1 H, piperdyl-2b-yl), 4.31–4.43 (m, 1 H, piperdyl-3-yl), 6.81
(dd, J = 8.1, 1.8 Hz, 1 H, Ph), 6.90 (s, 1 H, Ph), 6.95–7.04 (m, 3 H, Ph), 7.12 (t, J = 7.6 Hz, 1 H, Ph), 7.28 (t,
J = 7.8 Hz, 1 H, Ph), 7.38 (t, J = 7.9 Hz, 2 H, Ph), 7.68 (s, 1 H, H-6), 11.23 (s, 1 H, NH). 13C NMR (101
MHz, DMSO-d6) δ ppm 12.0 (1 C, 5-CH3), 23.9 (1 C, piperdyl-5-yl), 28.1 (1 C, piperdyl-4-yl), 32.3 (1 C,
PhCH2), 51.0 (1 C, piperdyl-3-yl), 52.2 (1 C, piperdyl-6-yl), 56.5 (1 C, piperdyl-2-yl), 59.2 (1 C, CH2N),
108.6 (1 C, C-5), 116.1 (1 C, Ph), 118.5 (2 C, Ph), 119.0 (1 C, Ph), 123.3 (1 C, Ph), 123.9 (1 C, Ph), 129.7 (1 C,
Ph), 130.0 (2 C, Ph), 138.0 (1 C, C-6), 142.7 (1 C, Ph), 150.8 (1 C, C-2), 156.5 (1 C, Ph), 156.7 (1 C, Ph),
163.7 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C24H27N3O3 + H]+ 406.2125, found 406.2125.
5-Methyl-1-(1-(2-(3-phenoxyphenyl)acetyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (26). To a solution
of 10b (0.2 g, 0.82 mmol) in MeOH (5.0 mL) was added 1M NaOH (5.0 mL), the resulting reaction
mixture was stirred at 50 ◦C for 2 h. After cooling to room temperature, the reaction mixture was
treated with 1N aq. HCl to pH 2–3. The generated white precipitate was collected through filtration
and dried in vacuo. The intermediate (0.17 g, 0.74 mmol), 28 (0.26 g, 0.79 mmol), EDC HCl (0.29 g,
1.5 mmol) and 4-dimethylaminopyridine (DMAP) (9.1 mg, 7.4 µmol) were dissolved in DCM (30 mL),
and the reaction mixture was stirred at room temperature for overnight to afford BOM protected
intermediate, which was deprotected with Pd/C (10%), H2 and HCOOH (0.5%) in i-propanol/H2O
(10/1 mL) [30] to give 26 (eluent system: 5% MeOH in DCM, 45 mg, 0.11 mmol, 13% yield). 1H NMR
(300 MHz, DMSO-d6) δ ppm 1.54–1.83 (m, 7 H, 5-CH3, piperdyl-3-yl, piperidyl-5-yl), 2.53–2.67 (m,
1 H, piperidyl-2/6-yl), 3.07 (t, J = 10.8 Hz, 1 H, piperidyl-2/6-yl), 3.59–3.85 (m, 2 H, COCH2), 4.05 (d,
J = 13.5 Hz, 1 H, piperidyl-2/6-yl), 4.43–4.56 (m, 2 H, piperidyl-4-yl, piperidyl-2/6-yl), 6.82–6.91 (m,
2 H, Ph), 6.95–7.03 (m, 3 H, Ph), 7.08–7.15 (m, 1 H, Ph), 7.31 (t, J = 7.8 Hz, 1 H, Ph), 7.34–7.41 (m, 2
H, Ph), 7.53 (d, J = 0.9 Hz, 1 H, H-6), 11.20 (s, 1 H, NH). 13C NMR (101 MHz, DMSO-d6) δ ppm 12.1
(1 C, 5-CH3), 29.7 (1 C, piperidyl-3/5-yl), 30.5 (1 C, piperidyl-3/5-yl), 38.9 (1 C, (CO)CH2), 40.8 (1 C,
piperidyl-2/6-yl), 44.7 (1 C, piperidyl-2/6-yl), 52.1 (1 C, piperidyl-4-yl), 109.1 (1 C, C-5), 116.7 (1 C, Ph),
118.7 (2 C, Ph), 119.5 (1 C, Ph), 123.5 (1 C, Ph), 124.4 (1 C, Ph), 129.9 (1 C, Ph), 130.1 (2 C, Ph), 137.7
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(1 C, Ph), 138.2 (1 C, C-6), 150.8 (1 C, C-2), 156.6 (1 C, Ph), 156.7 (1 C, Ph), 163.8 (1 C, C-4), 168.5 (1 C,
CO(CH2)). HRMS (ESI): m/z [M + H]+ Calcd. for [C24H25N3O4 + H]+ 420.1918, found 420.1925.
1-(3-Phenoxyphenethyl)-4-phenylpiperidine (27). To a solution of 12b (0.12 g, 0.56 mmol)
and 4-phenylpiperidine (0.14 g, 0.87 mmol) in dichloroethane (10 mL) was added sodium
triacetoxyborohydride (0.24 g, 1.1 mmol), the resulting mixture was stirred at room temperature for
overnight. The reaction mixture was diluted with DCM, and extracted with sat. NaHCO3 and brine.
The collected organic layer was dried, concentrated and purified to give 27 (58 mg, 0.16 mmol, 29%
yield). 1H NMR (300 MHz, CDCl3) δppm 1.91 (br. s., 4 H, piperdyl-3-yl, piperidyl-5-yl), 2.12–2.31 (m,
2 H, piperidyl-2a-yl, piperidyl-6a-yl), 2.46–2.62 (m, 1 H, piperidyl-4-yl), 2.65–2.77 (m, 2 H, CH2N),
2.83–2.97 (m, 2 H, PhCH2), 3.20 (d, J = 10.8 Hz, 2 H, piperidyl-2b-yl, piperidyl-6b-yl), 6.82 - 6.95 (m, 2
H, Ph), 6.96–7.07 (m, 3 H, Ph), 7.12 (t, J = 7.3 Hz, 1 H, Ph), 7.17–7.46 (m, 8 H, Ph). 13C NMR (75 MHz,
CDCl3) δppm 33.0 (2 C, piperdyl-3-yl, piperidyl-5-l), 33.2 (1 C, PhCH2), 42.4 (1 C, piperidyl-4-yl),
54.1 (2 C, piperidyl-2-yl, piperidyl-6-yl), 60.3 (1 C, CH2N), 116.5 (1 C, Ph), 118.8 (1 C, Ph), 119.1 (1 C,
Ph), 123.2 (1 C, Ph), 123.6 (1 C, Ph), 126.2 (1 C, Ph), 126.8 (3 C, Ph), 128.4 (2 C, Ph), 129.6 (1 C, Ph),
129.7 (2 C, Ph), 142.1 (1 C, Ph), 145.9 (1 C, Ph), 157.1 (1 C, Ph), 157.8 (1 C, Ph). HRMS (ESI): m/z [M +
H]+ Calcd. for [C25H27NO + H]+ 358.2166, found 358.2164.
4. Conclusions
Starting from the earlier reported compound 3, 19 analogs were synthesized and evaluated for
the inhibitory potencies of both MtbTMPK and M. tuberculosis (H37Rv) in vitro growths. Selected
substituents on the terminal phenyl ring slightly improved the inhibitory potency. Surprisingly, the 3-Cl
analog (21j) was three-fold more potent than compound 3 as the MtbTMPK inhibitor. Substitution
of the distal phenyl ring of 3 and 21n afforded analogs with superior whole cell antimycobacterial
activity compared to 3. These results provide possible directions for further investigations of MtbTMPK
inhibitors as antituberculosis agents.
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